紫杉醇和顺铂同步放化疗治疗宫颈癌腺癌。

Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix.

机构信息

Department of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, Okinawa, Japan.

出版信息

Anticancer Res. 2012 Apr;32(4):1475-9.

Abstract

BACKGROUND

It is unclear whether cisplatin-based concurrent chemoradiotherapy (CCRT) has the same effect on adenocarcinoma as on squamous cell carcinoma.

PATIENTS AND METHODS

We retrospectively analyzed data for 32 patients with stage IIB-IVA cervical adenocarcinoma who were treated with radiotherapy (RT) or CCRT. Fourteen patients were treated with RT, 8 with CCRT using cisplatin alone (CCRT-P), and 10 with CCRT using cisplatin plus paclitaxel (CCRT-TP).

RESULTS

Complete response was achieved in 7/14 patients in the RT group, 4/8 patients in the CCRT-P group, and 9/10 patients in the CCRT-TP group. Ten out of the 14 patients in the RT, 7/8 patients in the CCRT-P, and 2/10 patients in the CCRT-TP groups experienced locoregional recurrence. The 5-year overall survival rate in the RT, CCRT-P, and CCRT-TP groups was 7.1%, 25.0%, and 74.1%, respectively (p=0.0094).

CONCLUSION

The present study demonstrated that CCRT-TP achieved much better local control for adenocarcinoma of the cervix, leading to a decrease in locoregional recurrence.

摘要

背景

顺铂为基础的同期放化疗（CCRT）对腺癌的效果是否与鳞状细胞癌相同尚不清楚。

患者与方法

我们回顾性分析了 32 例接受放疗（RT）或 CCRT 治疗的 IIB-IVA 期宫颈腺癌患者的数据。14 例患者接受 RT 治疗，8 例患者接受单纯顺铂 CCRT（CCRT-P）治疗，10 例患者接受顺铂联合紫杉醇 CCRT（CCRT-TP）治疗。

结果

RT 组 7/14 例患者达到完全缓解，CCRT-P 组 4/8 例患者达到完全缓解，CCRT-TP 组 9/10 例患者达到完全缓解。RT 组 14 例患者中有 10 例、CCRT-P 组 8 例患者中有 7 例、CCRT-TP 组 10 例患者中有 2 例发生局部区域复发。RT、CCRT-P 和 CCRT-TP 组的 5 年总生存率分别为 7.1%、25.0%和 74.1%（p=0.0094）。